摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3-(4-苄基哌嗪-1-基)-1-羟基-2-甲基丙基)苯酚 | 375856-62-5

中文名称
4-(3-(4-苄基哌嗪-1-基)-1-羟基-2-甲基丙基)苯酚
中文别名
——
英文名称
threo-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol
英文别名
α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol;α-(4-hydroxyphenyl)-βmethyl-4-(phenylmethyl)-1-piperidinepropanol;4-(3-(4-Benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl)phenol;4-[3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol
4-(3-(4-苄基哌嗪-1-基)-1-羟基-2-甲基丙基)苯酚化学式
CAS
375856-62-5
化学式
C22H29NO2
mdl
——
分子量
339.478
InChiKey
WVZSEUPGUDIELE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    512.4±45.0 °C(Predicted)
  • 密度:
    1.116±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    25
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    43.7
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(3-(4-苄基哌嗪-1-基)-1-羟基-2-甲基丙基)苯酚dimethyl sulfide borane 作用下, 以 四氢呋喃 为溶剂, 以60%的产率得到4-[3-(4-Benzylpiperidin-1-yl)-2-methylpropyl]phenol
    参考文献:
    名称:
    Discovery of (R)-1-[2-Hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: A Novel NR1/2B Subtype Selective NMDA Receptor Antagonist
    摘要:
    Starting from Ro-25-6981 as a lead compound, highly potent and selective NR1/2B subtype selective NMDA receptor antagonists, with low activity at alpha (1) adrenergic receptors were developed. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(01)00392-4
  • 作为产物:
    描述:
    参考文献:
    名称:
    Discovery of (R)-1-[2-Hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: A Novel NR1/2B Subtype Selective NMDA Receptor Antagonist
    摘要:
    Starting from Ro-25-6981 as a lead compound, highly potent and selective NR1/2B subtype selective NMDA receptor antagonists, with low activity at alpha (1) adrenergic receptors were developed. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(01)00392-4
点击查看最新优质反应信息

文献信息

  • [EN] NEW HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES AMIDES D'ACIDE CARBOXYLIQUE HETEROCYCLIQUE
    申请人:RICHTER GEDEON VEGYESZET
    公开号:WO2006010969A1
    公开(公告)日:2006-02-02
    The invention relates to new heterocyclic carboxylic acid amide derivatives of formula (I) - wherein the meaning of X is hydrogen or halogen atom, hydroxy, cyano, C1-C4 alkylsulfonamido optionally substituted by a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted by a halogen atom or halogen atoms, arylsulfonamido groups, is -CH= group or -N= atom, Z is one or more hydrogen or halogen atom, C1-C4 alkyl, C1-C4 alkoxy, cyano, trifluoromethyl, trifluoromethoxy group and to the salts thereof, which are antagonists of NMDA receptor or are intermediates for preparing thereof.
    该发明涉及公式(I)的新杂环羧酸酰胺衍生物,其中X的含义是氢或卤素原子,羟基,氰基,C1-C4烷基磺酰胺(可选择地由卤素原子或卤素原子取代),C1-C4烷酰胺(可选择地由卤素原子或卤素原子取代),芳基磺酰胺基团,-CH=基团或-N=原子,Z是一个或多个氢或卤素原子,C1-C4烷基,C1-C4烷氧基,氰基,三氟甲基,三氟甲氧基团及其盐,这些衍生物是NMDA受体的拮抗剂或用于其制备的中间体。
  • [EN] KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS<br/>[FR] DERIVES AMIDES D'ACIDE KYNURENIQUE UTILISES EN TANT QU'ANTAGONISTES DE RECEPTEURS DE NR2B
    申请人:RICHTER GEDEON VEGYESZET
    公开号:WO2006010967A1
    公开(公告)日:2006-02-02
    The new kynurenic acid amide derivatives of formula (I): and optical antipodes, racemates and the salts thereof are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.
    公式(I)的新型酮尿酸酰胺衍生物及其光学对映体、外消旋体和盐类是NMDA受体的高效选择性拮抗剂,而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。
  • Method for preventing dyskinesias
    申请人:——
    公开号:US20030004187A1
    公开(公告)日:2003-01-02
    Dyskinesias in humans are prevented by administering a therapeutically effective dose of a NR1A/2B site-selective NMDA receptor antagonist compound to a human.
    在人类中,通过给予治疗有效剂量的NR1A/2B位点选择性NMDA受体拮抗剂化合物,可以预防运动失调症状。
  • [EN] PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PIPERIDINE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR N-METHYL-D-ASPARTATE (NMDA)
    申请人:RICHTER GEDEON VEGYESZET
    公开号:WO2003010159A1
    公开(公告)日:2003-02-06
    The present invention relates to new carboxylic acid amide derivatives of formula (I), wherein U, V, W, X, Y, Z, n and m are as defined as in Claim 1. A further object of the invention are the processes for producing of carboxylic acid amide compounds of formula (I), and the pharmaceutical manufacture of medicaments containing these compounds, as well as the process of treatments with these compounds, which means administering to a mammal to be treated including human - effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament. The new carboxylic acid amide derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.
    本发明涉及公式(I)的新羧酸酰胺衍生物,其中U、V、W、X、Y、Z、n和m如权利要求书1中所定义。本发明的另一个目标是制备公式(I)的羧酸酰胺化合物的过程,以及包含这些化合物的药物制剂的制药制造,以及使用这些化合物进行治疗的过程,即向待治疗的哺乳动物(包括人类)施用本发明的公式(I)的化合物或药物的有效量/剂量。本发明的新羧酸酰胺衍生物是高效且选择性的NMDA受体拮抗剂,而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。
  • [EN] AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS<br/>[FR] DERIVES AMIDIQUES COMME ANTAGONISTES DU RECEPTEUR NMDA
    申请人:RICHTER GEDEON VEGYESZET
    公开号:WO2002034718A1
    公开(公告)日:2002-05-02
    The invention relates to new NR2B selective NMDA receptor antagonist carboxylic acid amide derivatives of formula (I) as well as the recemates, optical antipodes and the salts thereof formed with acids and bases. Fruthermore objets of the present invention are the pharmaceutical compositions containing compounds of formula (I) or the salts thereof as active ingredients, as well as the synthesis of compounds of formula (I), and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the method of treatments with these compounds, which means administering to a mammal to be treated - including human - effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament. The new carboxylic acid amide derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.
    本发明涉及公式(I)的新型NR2B选择性NMDA受体拮抗剂羧酸酰胺衍生物,以及与酸和碱形成的外消旋体,光学对映体和其盐。此外,本发明的目标是含有公式(I)化合物或其盐作为活性成分的制药组合物,以及公式(I)化合物的合成,以及含有这些化合物的药物的化学和制药制造,以及使用这些化合物的治疗方法,即向待治疗的哺乳动物(包括人类)施用本发明的化合物的有效量/量,作为药物或单独使用。本发明的新型羧酸酰胺衍生物的公式(I)是高效和选择性的NMDA受体拮抗剂,而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。
查看更多